Abstract:Histone H3 lysine 4 (H3K4) methylation is closely correlated to gene transcription activation 1. In mammals, the MLL family (also called KMT2) histone methyltransferase, which includes MLL1 to 4, SET1A, and SET1B, are the principal enzymes that carry out the global methylation of H3K4 in vivo 1. In contrast to other SET domain-containing histone methyltransferases, MLL family proteins exhibit very low intrinsic histone methyltransferease (HMT) activity by themselves. Their full activity is only achieved in the presence of WDR5, Ash2L, RbBP5, and DPY30, the common regulatory components of all MLL family complexes 2. Ash2L (Absent, small or homeotic discs-like 2) is a trithorax group protein, and a critical regulator of all MLL complexes. Knockdown of Ash2L results in a global reduction of histone H3K4 trimethylation 3. The role of Ash2L in methylation regulation is dependent on its two binding partners, RbBP5 and DPY30 2, 4. The interaction between Ash2L and RbBP5 is essential for MLL1 complex integrity and activity regulation 2, 5. The Ash2L-DPY30 interaction was recently reported to be important for the regulation of nucleosomal H3K4 trimethylation and the differentiation potential of embryonic stem cells 6. Ash2L protein adopts a modular configuration. From the N- to the C-terminus, it contains a PHD finger, a WH motif, an SPRY domain, and a DPY-30 binding-motif (DBM) (Figure 1A). The SPRY domain is the primary moiety in Ash2L that recognizes RbBP5, mediates MLL1 complex assembly, and regulates MLL1 enzymatic activity 5. Here we report the crystal structure of SPRY domain of Ash2L, and dissect its interactions with RbBP5 and DPY30. Bioinformatical and biochemical analyses suggested that the SPRY domain of Ash2L contains a large 44-residue unstructured loop (residues 402-445) in the middle of the domain (Supplementary information, Figure S1A, S1B and S1C). An Ash2L construct (Ash2LSPRY) with a deletion of this loop retains the same HMT activity as the full-length Ash2L (Supplementary information, Figure S1D). We determined the crystal structure of Ash2LSPRY using the single-wavelength anomalous dispersion method with mercury (MeHgAc)-derivative crystals, and refined to a resolution of 2.1 Å (Supplementary information, Table S1). The high-quality experimental electron density map enabled us to fit and refine the structure except for the C-terminal 13 residues (residues 511-523). Ash2LSPRY adopts a tadpole-like conformation with three recognizable modules, an 11-residue N-terminal pre-SPRY motif, a central 200-residue globular fold that forms the core of Ash2LSPRY, followed by a 25-residue C-terminal post-SPRY motif (Figure 1B). Both the pre-SPRY and the post-SPRY motifs are short and composed of a 310 helix and either one or two β strands (Figure 1B). These two motifs form a two-stranded β sheet that protrudes from the globular SPRY domain, forming the tail of the tadpole-like structure (Figure 1B). The post-SPRY motif makes extensive contacts with one side of the β-sandwich of Ash2LSPRY and thus plays an important role in stabilizing the core of the SPRY domain (Supplementary information, Figure S2A). The central core of Ash2LSPRY adopts a distorted β-sandwich conformation, consisting of two layers of concave-shaped β-sheets (Figure 1B). All these β strands are arranged in an anti-parallel configuration. The two β-sheet layers stack together mainly through Van der Waals contacts by a group of hydrophobic residues (Supplementary information, Figure S2B). These internal hydrophobic residues are evolutionarily conserved from yeast to humans (Supplementary information, Figure S3), suggesting that all the Ash2L homologs share the similar SPRY fold as the human Ash2LSPRY. The deleted 44-residue loop F' between strands β11 and β12, is away from the structural core, and thus is dispensable for the stability of the Ash2LSPRY domain (Figures 1B). Of note, sequence alignment shows that the yeast Bre2 protein, a distant homolog of human Ash2L, contains two large loops, a 40-residue loop between strands β6 and β7 and another 112-residue loop connecting β11 and β12 (Supplementary information, Figure S3). The crystal structure of Ash2LSPRY closely resembles other SPRY domains (Supplementary information, Figure S4). Ash2LSPRY has several unique features compared with other SPRY domains. Most notably, Ash2LSPRY contains both a pre- and a post-SPRY motifs and the latter is essential for the correct folding of the protein (Supplementary information, Figure S2A). In contrast, all other SPRY domains with known structures to date lack the post-SPRY motif. Secondly, the connecting loop regions have great variation in Ash2LSPRY compared with other SPRY domains (Supplementary information, Figure S3). These structural disparities in the loop regions are likely correlated with their different roles in specific protein recognition. Another unique feature of Ash2L is the dimerization of Ash2LSPRY found in the crystal structure (Supplementary information, Figure S5A and S5B). However, the affinity of the observed dimeric interface is too weak to stably hold two Ash2LSPRY molecules together in vitro (Supplementary information, Figure S5C and S5D). In addition, Ash2L dimerization appears to have no effect on the HMT activity of the MLL1 complex (Supplementary information, Figure S5E). Further investigation is needed to clarify the in vivo function of Ash2LSPRY dimerization. Recent studies revealed that the SPRY domain of Ash2L recognizes a stretch of acidic residues of RbBP5 5, 7. We presumed that the interaction between Ash2L and RbBP5 is very likely mediated by electrostatic contacts. Consistent with this notion, our previous data showed that Arg343 of Ash2L is important for RbBP5 binding 5. Arg343 is localized at a highly positively charged surface formed by strands β7, β8 and loop E of Ash2LSPRY (Figure 1C). This observation led us to hypothesize that this basic concaved surface on Ash2LSPRY might be the binding site for RbBP5. To test this idea, we examined whether mutations of residues on the predicted Ash2L-RbBP5 interface could weaken or disrupt the Ash2L-RbBP5 interaction. In support of our model and consistent with our previous results, alanine substitution of the conserved Arg343 of Ash2LSPRY was sufficient to completely abolish the interaction with RbBP5 in the ITC assay (Figure 1D). Similarly, alanine mutation of another arginine residue Arg367 also impaired the interaction (Figure 1D). In addition, several other positively charged residues of Ash2LSPRY (Lys369, Lys370, and Lys476) also play roles in RbBP5 interaction, as mutations of all these residues weaken the interaction to varying degrees (Figure 1D). Moreover, these RbBP5 binding-deficient mutants showed partial or complete loss of ability to stimulate the HMT activity of MLL1, in a manner consistent with the severity of the Ash2L-RbBP5 interaction defect (Figure 1E). Taken together, we conclude that the identified basic surface on Ash2LSPRY is necessary for the binding to RbBP5. All the mutant proteins described above displayed unaltered biophysical properties, as analyzed by gel-filtration chromatography (data not shown), assuring that the altered affinity of the mutants for RbBP5 is not attributable to a change in the structural integrity of the resulting proteins. Ash2LSPRY employs a novel molecular surface to interact with RbBP5, as shown by the comparison with structures of other SPRY domain-containing complexes (Supplementary information, Figure S6), reinforcing the notion that SPRY domain is a diversified protein-protein interaction module. Beside RbBP5, another important Ash2L-binding partner is DPY30 4. The C-terminus of Ash2L (residues 508-534) has been proposed to mediate the interaction with DPY30 8. We further characterized the Ash2L-DPY30 interaction by an in vitro GST-pull-down assay. Both the full-length DPY30 and its C-terminal dimerization domain (DPY30DD; residues 45-99) could efficiently pull-down Ash2L, suggesting that DPY30DD is sufficient for the interaction with Ash2L (Supplementary information, Figure S7A). Next, various constructs of Ash2L that contain the SPRY domain and end at different positions at the C-terminus of Ash2L were evaluated for their ability to interact with DPY30DD. The Ash2LSPRY construct used for the structural study (residues 276-523) retained the binding activity with DPY30, whereas the construct ending at residue 510 failed to bind to DPY30 (Figure 1F). This result suggested that a short 14-residue C-terminal fragment of Ash2L (residues 510-523) is required for the interaction with DPY30. Notably, this short fragment was also found to be sufficient for DPY30 binding (Figure 1F). Although Ash2L510-523 was included in the crystallization construct of Ash2LSPRY, residues 510-523 are not visible in the electron-density map, indicating that the Ash2LDBM peptide is not part of the compact SPRY domain. DPY30DD adopts a canonical four-helix-bundle conformation with extensive hydrophobic surface 9. The structure of DPY30DD is similar to that of PKA RIIa, the RIIa isoform of a cAMP-dependent protein kinase 10. The two structures can be superimposed with an r.m.s.d. value of 2.1 Å (Supplementary information, Figure S7B). In the PKA-RIIa/D-AKAP2 complex, the D-AKAP2 peptide forms a helical structure and binds to the hydrophobic cleft on the dimeric interface of PKA RIIa 10. Notably, secondary structure prediction analysis suggested that, similar to the D-AKAP2 helix, residues 510 to 523 of Ash2L also likely adopt an α-helical structure (data not shown). Therefore, we hypothesized that Ash2LDBM might bind to DPY30 in a similar manner to the D-AKAP2 helix in the PKA-RIIa/D-AKAP2 complex. Sequence alignment of Ash2LDBM with the D-AKAP2 peptide revealed that the hydrophobic residues that are involved in the complex formation in the PKA-RIIa/D-AKAP2 complex are well-conserved in Ash2L (Supplementary information, Figure S7C). Based on these analyses, we generated a model structure of Ash2LSPRY complexed with DPY30DD (Figure 1G). In this model, the Ash2L-DPY30 interaction is mainly mediated by hydrophobic contacts; Ash2L residues Val509, Leu513, Val516, Leu517, and Val520 from one side of the Ash2LDBM helix fit into the hydrophobic groove formed by a group of hydrophobic residues from the α1 helix of both DPY30DD protomers (Leu57, Val61, Leu65, Leu66, and Met69) (Figure 1G). This is consistent with previous results that substitution of DPY30 Leu65 and Leu66 with glutamates completely abolished the interaction with Ash2L 8. To further corroborate our structural model, we generated a series of Ash2L mutants and examined the effects of these mutations on the Ash2L-DPY30 interaction. Despite mutations of individual Ash2L residues on the Ash2L-DPY30 interface only slightly weakened the interaction, a triple Ash2L mutation L513E/L517E/V520E completely disrupted the interface (Figure 1H). A definitive confirmation of this interaction model between Ash2LDBM and DPY30DD has to wait until the atomic structure of the Ash2LDBM-DPY30DD complex becomes available. Nonetheless, our structural and biochemical data showed that DPY30 and RbBP5 bind to different sites on Ash2LSPRY, suggesting that they mediate independent interactions with Ash2L. Consistent with this idea, addition of DPY30 had no effect on the interaction between Ash2LSPRY and RbBP5 (Supplementary information, Figure S7D). In the present work, we report the crystal structure of the C-terminal SPRY domain of human Ash2L. Our structural and biochemical analyses reveal a basic surface on Ash2L as the RbBP5-binding interface, and demonstrate that this interface is crucial for both RbBP5 binding and MLL1 methyltransferase activity regulation. We also determine the minimum motif of Ash2L that is required for DPY30 interaction, and propose a structural model for the Ash2L-DPY30 interaction. Together, these results provide a framework for the further investigation of the structure of the MLL complexes. ML acknowledges generous financial support from NIH (RO1 GM083015) and the American Cancer Society. ML is a Howard Hughes Medical Institute Early Career Scientist. The General Medicine and Cancer Institutes Collaborative Access Team has been funded in whole or in part by federal grants from the National Cancer Institute (Y1-CO-1020) and the National Institute of General Medical Science (Y1-GM-1104). Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract No DE-AC02-06CH11357. (Supplementary information is linked to the online version of the paper on the Cell Research website.)

Abstract:Polyamines including putrescine, spermidine, and spermine are important polycationic small molecules for life. They are involved in protein synthesis, cell growth, and regulation of several metabolic processes in a cell.1 Overaccumulation of the polyamines is toxic to cells. The intracellular concentration of polyamines is carefully controlled by a combination of regulated enzymatic steps, including biosynthetic enzymes such as ornithine decarboxylase, and catabolic enzymes such as spermidine/spermine N1-acetyltransferase (SSAT).2, 3 SSAT is one of the diamine N-acetyltransferases and a rate-limiting enzyme, which has a key role in polyamine metabolism. It catalyzes the N1-acetylation of spermine and spermidine to form less charged derivatives that are either excreted from the cell or undergo further metabolism. It is the turning point of the polyamine metabolism pathway.4 So far 11 proteins have been identified as belonging to the SSAT homologous family, as shown in Figure 1. Although the function of SSAT is important, the three-dimensional structure as well as the mechanism of enzyme reaction and actual activity site of SSAT are still unknown. Secondary structure of hSSAT and sequence alignment between SSAT proteins and Hpa2. SSAT = spermidine/spermine N1-acetyltransferase. Hpa2 is the histone acetyltransferase from yeast. The secondary-structure elements (β-sheet, α-helix) found in hSSAT are shown above the sequence. The identical and homologous residues are shaded in dark gray and light gray, respectively. The consensus sequence for the acetyl CoA binding site is highlighted by box. Eleven aligned SSAT homologous proteins were obtained from UniProt.21 The sequence alignment was performed with ClustalW22 and the figure was prepared with ALSCRIPT.23 Human SSAT (hSSAT), containing 171 residues, is related with many serious diseases, such as human colon cancer and infection of human immunodeficiency virus-1.5, 6 Herein, we report the crystal structure of hSSAT, which is the first structure of diamine N-acetyltransferases. The fold of hSSAT belongs to the transferase homologous superfamily. The comparisons of sequence and structure show that the hSSAT structure is the representative of a new sequence family of transferase superfamily. Three-dimensional structure also suggests the potential enzyme activity site of hSSAT. Polymerase chain reaction primers, including NdeI and XhoI restriction sites, were designed to amplify the hSSAT gene (GenBank: NP_002961) from reverse transcriptase-polymerase chain reaction products of human hemopoietic stem cell. The gene was inserted into the pET22b(+) vector (Novagen), and the recombinant protein was overexpressed as a C-terminal His-tagged protein in Escherichia coli BL21(DE3). The cells were grown in LB at 37°C and induced with 1 mM IPTG when the culture reached an O.D600 of 0.6–0.8. The harvested cells were resuspended in the lysis buffer (50 mM NaH2PO4, pH8.0; 300 mM NaCl; 10 mM imidazole) with 0.1 mM PMSF and sonicated. The lysate was centrifuged at 15,000 revolutions per minute (rpm) at 4°C for 20 min. The supernatant was loaded directly into a Ni-NTA column (Novagen) preequilibrated with lysis buffer. Then the column was washed with wash buffer (50 mM NaH2PO4, pH8.0; 300 mM NaCl; 20 mM imidazole) and the target protein was eluted with elution buffer (50 mM NaH2PO4, pH 8.0; 300 mM NaCl; 250 mM imidazole). The eluate was concentrated by ultrafiltration (Millipore) and then loaded into a Superdex75 HR16/60 column (Amersham Pharmacia) preequilibrated with buffer of 20 mM Tris-HCl pH 8.0 at 16°C. Further purification was performed with a global Mono Q HR5/5 (Amersham Pharmacia). Finally, hSSAT was desalted with the buffer of 20 mM Tris-HCl pH 8.0. The purified protein was analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The purified protein was concentrated to 50 mg/mL for crystallization. Crystallization experiments were performed with the hanging-drop vapor-diffusion method combined with micro-seeding at 20°C. The diffusion drops were formed with 1 μL of protein solution and 1 μL of reservoir solution and seeded immediately. Then the drops were equilibrated against 0.5 mL of reservoir solution containing 2.6 M NaCl, 0.1 M Tris-HCl pH 8.0, and 0.1 M potassium sodium tartrate. The qualified crystals suitable for X-ray diffraction were obtained after one night. All diffraction data were collected on a Rigaku FRE diffraction system using a Rigaku R-Axis IV++ image plate detector. For preparation of the iodine-derivative crystals, quick-soaking method was used. The crystal was soaked in the heavy-atom soaking solution (2.6 M NaCl, 0.1 M Tris-HCl, 0.1 M potassium sodium tartrate and 0.5 M KI) for 30 s before mounting the crystal. Native crystal was soaked the same way using native-soak solution (2.6 M NaCl, 0.1 M Tris-HCl pH 8.0, and 0.1 M potassium sodium tartrate) to maintain the same isomorph. Then the crystals were flash-cooled in the nitrogen-gas stream at 95 K. Two sets of data were collected with the crystal-to-detector distance of 220 mm and exposed for 3 min with 1° oscillation per frame. The iodine-derivative data were collected to 360 frames and native data to 107 frames. MOSFLM, SCALA, and TRUNCATE from the CCP4 program suite7 were used for processing, reduction, and scaling of the diffraction data. Data statistics are summarized in Table I. The structure of hSSAT was successfully determined through the iodine short-cryo soaking approach.8 The program SHELXD was used to search initial iodine atom sites. The iodine atom sites were detected again and refined by SHARP9 using isomorphous and anomalous signals. There are 22 iodine sites found in an asymmetric unit. After initial phasing by SHARP and density modification by SOLOMON, further density modification was performed with DM10 (average) from the CCP4 program suit7 to refine the phase. The initial model consisting of 70% of the hSSAT structure was built automatically by using ARP/wARP.7, 11 The remainder of the model was manually built using O.12 The structure was refined to the resolution of 2.3 Å with CNS version 1.1.13 The final model was built up with R-factor of 0.201 and Rfree of 0.269. The quality of the structure was checked using PROCHECK.14 The statistics are listed in Table I. The final structure model of hSSAT contains two protein molecules (residues 3–169 for chain A, residues 3–170 for chain B) and 359 water molecules. The whole hSSAT sequence has 171 residues. Because of lack of electron density, seven residues at N- and C-terminal, including A1, A2, A170, A171, and B1, B2, B171, are missed. The His-tag at C-terminal also does not appear in the electron density map. Two residues (Glu-B48 and Glu-B67) are in disallowed regions of the Ramachandran plot, which are well defined by the clear density maps. At the moment, there is no special reason to be found for these strained conformations. There are two hSSAT molecules related by a noncrystallographic twofold axis in the asymmetric unit, which are integrated into a stable dimer via a unique way [Fig. 2(a)]. The tertiary structure of the hSSAT monomeric partner adopts a compact α/β fold mode, which consists of seven β-strands which consists of seven β-strands (β1–β7) connected by six α-helices (α1–α2, α4–α7) and a 310 helix (α3) [Fig. 2(b)]. The core structure of monomer contains a central five-stranded antiparallel β-sheet (β1–β5) and four helices (α1–α4). The helices of α1 and α2 connect strands β1 and β2 and are located on the convex face of this five-stranded antiparallel β-sheet, whereas the helices of α3 and α4, which connect strands β4 and β5, are located on the concave face. It is interesting that the remaining structural elements at the C-terminal, including α5, β6, α6, β7, and α7, are rather separately arranged out of the core structure to form a long tail of the tertiary structure [Fig. 2(b)]. Evidently, this separated C-terminal segment needs to be stabilized by special structural factors. Actually, this special structural requirement is notably satisfied by the dimerization of two hSSAT molecules. In the dimeric form of hSSAT, the long β-strand at C-terminal, β7 of one molecule, is subtly inserted into the space between β5 and β6 of the partner molecule to form a heterogeneous three-stranded antiparallel β-sheet through 11 pairs of intermolecular main-chain hydrogen bonds (eight between residues 123–131 of Mol A and residues 153–161 of Mol B and three between residues 146–149 of Mol A and residues 158–156 of Mol B) [Fig. 2(c)]. This heterogeneous three-stranded β-sheet is further combined with β1–β4 to construct an integrated seven-stranded antiparallel β-sheet as a more stable molecular scaffold for hSSAT monomer. By accompanying, the C-terminal helix α7 of one molecule is also moved and stabilized by interacting with helix α4 of the partner molecule [Fig. 2(c)]. We refer to this unique way for the dimerization of hSSAT as C-terminal exchange. Through C-terminal exchange, two hSSAT molecules are firmly assembled to an intact dimer, which is the main structural character of hSSAT. It implies that the dimeric form of hSSAT is its basic structural and functional unit. In fact, our experiment data showed that hSSAT is really a dimer in solution (data not shown here). a: Ribbon diagram of hSSAT dimer. Ribbons are colored in orchid and green for molecule A and B, respectively. Two molecules are related by a noncrystallographic twofold axis. b: Diagram of hSSAT monomer structure. β1–β5 and α1–α4 as the core structure are shown in green. The separated C-tail of the molecule consisting of β6–β7 and α5–α7 is shown in red. The β7-strand from the opposite molecule will be inserted into the space between β5 and β6 in dimeric form. c: C-terminal exchange and interaction segments in hSSAT dimer. α4–α7 and β5–β7 are from molecule A (orchid). α4′–α7′ and β5′–β7′ are from opposite molecule B (green). In dimerization, the strand β7 at the C-terminal of A is inserted into the space between β5′ and β6′ of B to form a heterogeneous three-stranded β-sheet, which will further contact the sheet of β1′–β4′ to build up a more stable molecular scaffold (shown in a and b). By accompanying, the C-terminal helix α7 of molecule A is moved to contact with α4′ of molecule B. The figures were prepared using Molscript.24 The structure similarity search with Dali revealed that the core fold of hSSAT, consisting of six strands with four surrounding α-helices, is generally consistent with the typical transferase fold in CATH,15, 16 in which the protein domain structures are hierarchically classified. Through analysis with the combinatorial extension (CE),17 all of the structures similar to hSSAT belong to the transferase family. So it strongly identified that hSSAT belongs to the transferase homologous superfamily (CATH code: 3.40.630.30). So far, there are 22 sequence families found in the transferase homologous superfamily. The PSI-BLAST18 result indicates that there is no obvious sequence similarity between hSSAT and all other structures of the transferase homologous family. Further sequence comparison was performed with SSAP.19 It indicates that hSSAT has less than 20% sequence identity to each representative member of 22 sequence families. According to CATH criteria of S-level classification, hSSAT should be assigned to a new sequence family of the transferase homologous superfamily. The structural comparisons showed that the closest structural homolog of hSSAT was the histone acetyltransferase Hpa220 from yeast (Hpa2, PDB ID 1QSM; SSAP score, 85.03%, overlap, 88%; root-mean-square deviation, 2.47 Å for equivalent 147 aligned residues). However, there is only 16% sequence identity between hSSAT and Hpa2. The main structure difference between these two structures is located at the C-terminal segment where hSSAT has an additional α helix (α7). Hpa2 is a member of the Gcn5-related N-acetyltransferase (GNAT) family. It has a conserved acetyl CoA binding site, which is characterized with the sequence of RXXGXG (X can be any amino acid residue).20 This characterized sequence is also conserved in 11 proteins of the SSAT family (residues 101–106 with sequence RGFGIG) (Fig. 1). The structural comparison between hSSAT and Hpa2-acetyl CoA complex showed that hSSAT has a similar tertiary structure at this acetyl CoA binding site. It indicates that hSSAT should adopt a similar acetyl CoA binding site and activity site as Hpa2. The hSSAT is the first structure of diamine N-acetyltransferases and the SSAT homologous family. So far, the detailed mechanism of bioactivity of hSSAT is still in question. The tertiary structure of hSSAT reported in this article provides a sound basis for the in-depth study of its structure–function relationship. Coordinates and structure factors for the structure of hSSAT have been deposited at the Protein Data Bank with accession code 2F5I. The X-ray data collection was supported by the Photon Factory at KEK (20005G253), Japan. The authors thank Yi Han of the protein platform of Institute of Biophysics for providing the X-ray facility in house for crystallographic analysis and data collection.

Structure of the SPRY domain of human Ash2L and its interactions with RbBP5 and DPY30

Mechanism for DPY30 and ASH2L intrinsically disordered regions to modulate the MLL/SET1 activity on chromatin

Crystal Structure of the N‐terminal Region of Human Ash2L Shows a Winged‐helix Motif Involved in DNA Binding

Crystal Structure Of Human Spermidine/Spermine N'-Acetyltransferase (Hssat): The First Structure Of A New Sequence Family Of Transferase Homologous Superfamily

Structural Insights into Stimulation of Ash1L's H3K36 Methyltransferase Activity Through Mrg15 Binding.

The Ash2l SDI Domain Is Required to Maintain the Stability and Binding of DPY30

An Ash2l/Rbbp5 Heterodimer Stimulates The Mll1 Methyltransferase Activity Through Coordinated Substrate Interactions With The Mll1 Set Domain

Crystal structure and functional characterization of the human RBM25 PWI domain and its flanking basic region.

Crystal Structure of the C-Terminal Domain of Human Dpy-30-Like Protein: A Component of the Histone Methyltransferase Complex

DPY30 acts as an ASH2L-specific stabilizer to stimulate the enzyme activity of MLL family methyltransferases on different substrates

Mammalian Ash1l is A Histone Methyl Transferase That Occupies the Transcribed Region of Active Genes

MRG15 activates histone methyltransferase activity of ASH1L by recruiting it to the nucleosomes

Ash2l Interacts with Tbx1 and is Required During Early Embryogenesis

Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase

Arabidopsis SWR1-associated Protein Methyl-Cpg-binding Domain 9 is Required for Histone H2A.Z Deposition

Solution Structure of Human Brg1 Bromodomain and Its Specific Binding to Acetylated Histone Tails.

Structural Basis and Binding Properties of the Second Bromodomain of Brd4 with Acetylated Histone Tails.

Structural and Histone Binding Ability Characterization of the ARB2 Domain of a Histone Deacetylase Hda1 from Saccharomyces Cerevisiae

Crystal Structure of Human SSRP1 Middle Domain Reveals a Role in DNA Binding

ASH1L links histone H3 lysine 36 di-methylation to MLL leukemia.

Structural Basis for Specific Binding of Human MPP8 Chromodomain to Histone H3 Methylated at Lysine 9.